The clinical activity of RG7155 was evaluated in patients with diffuse-type giant cell tumor and was shown to induce a striking reduction in the CSF-1R+CD163+ macrophage population within tumor tissues [106]. This evidence concerns the gene CD163 and tenosynovial giant cell tumor, diffuse type.